Figure 8.

AZA treatment maintains graft-vs.-leukemia effect in NSG-HLA-A2/HHD mice. (A, B) NSG-HLA-A2/HHD mice were transplanted with 2 × 10⁷ human PBMC i.v. and were treated or not with AZA subcutaneously every 48 h at doses of 5 mg/kg starting on day +1 until day +21. Survival (A) and xGVHD scores (B) were monitored (n = 5–6 / condition). (C, D) NSG-HLA-A2/HHD mice were transplanted with 3 × 10⁶ THP-1-luc cells together or not with 2 × 10⁷ human PBMC. Mice were either treated or not with AZA 5 mg/kg and survival (C) and bioluminescence (D) were monitored. Actual images of one representative mouse from each group are shown with Y-axis indicating photon flux (photons/sec) measured from the ventral view with a region of interest drawn over the entire body of each mouse. Right panels show the comparison of bioluminescence between groups. Data show median values with interquartile range (*p < 0.05, **p < 0.005, ***p < 0.0005).